403
Sorry!!
Error! We're sorry, but the page you were
looking for doesn't exist.
Vutrisiran Market Size Forecasted To Grow At 13.18% CAGR, Reaching USD 2.15 Billion By 2034
(MENAFN- EIN Presswire)
As per MRFR analysis, the Vutrisiran Market Growth Size was estimated at 0.62 (USD Billion) in 2024. The Vutrisiran Market Industry is expected to grow from 0.71 (USD Billion) in 2025 to 2.15 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 13.18% during the forecast period (2025 - 2034).
Top Vutrisiran Market Companies
MerckCo
Roche
Sanofi
AstraZeneca
Teva Pharmaceuticals
Pfizer
Ionis Pharmaceuticals
Alnylam Pharmaceuticals
Bristol Myers Squibb
Genzyme
GSK
AbbVie
Novartis
Regeneron Pharmaceuticals
Get Free Sample PDF Copy of This Report -
The Vutrisiran Market is experiencing significant growth driven primarily by the increasing prevalence of hereditary transthyretin amyloidosis (hATTR) and the rising awareness regarding genetic disorders. The need for innovative therapeutic solutions that address the challenges associated with hATTR is creating a surge in demand for Vutrisiran, which offers an effective treatment option. Additionally, advancements in biotechnology and drug delivery systems are facilitating the development of targeted therapies that harness the potential of Vutrisiran, further propelling market dynamics.
Industry Detailed Segmentation:
Vutrisiran Market Segmentation Insights
Vutrisiran Market Product Formulation Outlook
Injectable
Oral
Vutrisiran Market Therapeutic Area Outlook
Genetic Disorders
Cardiovascular Diseases
Neurological Disorders
Vutrisiran Market Distribution Channel Outlook
Hospital pharmacies
Retail pharmacies
Online pharmacies
Vutrisiran Market Patient Demographics Outlook
Pediatric
Adult
Geriatric
Vutrisiran Market Treatment Type Outlook
Monotherapy
Combination Therapy
Vutrisiran Market Regional Outlook
North America
Europe
South America
Asia Pacific
Middle East and Africa
The Vutrisiran Market, valued at 0.49 billion USD in 2023, reveals significant insights within its Treatment Type segment, primarily encompassing Monotherapy and Combination Therapy. Most of the market growth is driven by the rising adoption of innovative treatment modalities tailored to patient needs. Monotherapy plays a crucial role, catering to patients who require targeted interventions, thereby enhancing treatment efficacy and patient adherence. In contrast, Combination Therapy is gaining traction due to its ability to address complex cases and optimize treatment outcomes by leveraging the synergistic potential of multiple therapeutics.
Buy Now –
Key Benefits:
Addressing Unmet Medical Needs: hATTR is a progressive disease with limited treatment options. Vutrisiran offers a novel therapeutic approach by targeting the root cause of the disease, providing hope for patients who previously had few alternatives.
Increasing Prevalence and Awareness: Improved diagnostic techniques and heightened awareness have led to an increase in the diagnosed cases of hATTR. This expansion of the patient pool has contributed to the growing demand for effective treatments like vutrisiran.
Regulatory Approvals and Market Expansion: Vutrisiran has received approvals from major regulatory bodies, including the U.S. FDA and the European Medicines Agency, facilitating its availability across multiple regions. This has expanded the market reach and accessibility of the drug.
Favorable Market Projections: The global vutrisiran market was valued at approximately USD 600 million in 2022 and is projected to reach around USD 2,087 million by 2033, exhibiting a compound annual growth rate (CAGR) of 12% during the forecast period.
Strategic Collaborations: Partnerships, such as the collaboration between Alnylam Pharmaceuticals and AstraZeneca, have bolstered the development and commercialization efforts for vutrisiran, enhancing its market presence and potential.
Competitive Landscape: While vutrisiran faces competition from other treatments like Pfizer's Vyndaqel and BridgeBio Pharma's acoramidis, its unique mechanism of action and positive clinical trial outcomes position it as a strong contender in the market.
Read More Details -
Other Latest Healthcare Trending Insights
Upper Limb Prosthetic Market:
Urea Cycle Disorder Market:
Ureteral Dilators Market:
Urodynamic Equipment Market:
Ustekinumab Market:
UV Spectroscopy Market:
Vaccine Delivery Device Market:
Vaccine Research Market:
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
Vutrisiran Market
As per MRFR analysis, the Vutrisiran market Growth Size was estimated at 0.62 (USD Billion) in 2024.
US, NY, UNITED STATES, March 15, 2025 /EINPresswire / -- Vutrisiran is a therapeutic agent developed for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR), a rare and progressive genetic disorder characterized by the accumulation of misfolded transthyretin (TTR) proteins, leading to amyloid fibril deposits in various tissues and organs, including the nerves, heart, and kidneys. Utilizing RNA interference (RNAi) technology, vutrisiran targets and degrades TTR mRNA in the liver, thereby reducing the production of both wild-type and mutant TTR proteins.As per MRFR analysis, the Vutrisiran Market Growth Size was estimated at 0.62 (USD Billion) in 2024. The Vutrisiran Market Industry is expected to grow from 0.71 (USD Billion) in 2025 to 2.15 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 13.18% during the forecast period (2025 - 2034).
Top Vutrisiran Market Companies
MerckCo
Roche
Sanofi
AstraZeneca
Teva Pharmaceuticals
Pfizer
Ionis Pharmaceuticals
Alnylam Pharmaceuticals
Bristol Myers Squibb
Genzyme
GSK
AbbVie
Novartis
Regeneron Pharmaceuticals
Get Free Sample PDF Copy of This Report -
The Vutrisiran Market is experiencing significant growth driven primarily by the increasing prevalence of hereditary transthyretin amyloidosis (hATTR) and the rising awareness regarding genetic disorders. The need for innovative therapeutic solutions that address the challenges associated with hATTR is creating a surge in demand for Vutrisiran, which offers an effective treatment option. Additionally, advancements in biotechnology and drug delivery systems are facilitating the development of targeted therapies that harness the potential of Vutrisiran, further propelling market dynamics.
Industry Detailed Segmentation:
Vutrisiran Market Segmentation Insights
Vutrisiran Market Product Formulation Outlook
Injectable
Oral
Vutrisiran Market Therapeutic Area Outlook
Genetic Disorders
Cardiovascular Diseases
Neurological Disorders
Vutrisiran Market Distribution Channel Outlook
Hospital pharmacies
Retail pharmacies
Online pharmacies
Vutrisiran Market Patient Demographics Outlook
Pediatric
Adult
Geriatric
Vutrisiran Market Treatment Type Outlook
Monotherapy
Combination Therapy
Vutrisiran Market Regional Outlook
North America
Europe
South America
Asia Pacific
Middle East and Africa
The Vutrisiran Market, valued at 0.49 billion USD in 2023, reveals significant insights within its Treatment Type segment, primarily encompassing Monotherapy and Combination Therapy. Most of the market growth is driven by the rising adoption of innovative treatment modalities tailored to patient needs. Monotherapy plays a crucial role, catering to patients who require targeted interventions, thereby enhancing treatment efficacy and patient adherence. In contrast, Combination Therapy is gaining traction due to its ability to address complex cases and optimize treatment outcomes by leveraging the synergistic potential of multiple therapeutics.
Buy Now –
Key Benefits:
Addressing Unmet Medical Needs: hATTR is a progressive disease with limited treatment options. Vutrisiran offers a novel therapeutic approach by targeting the root cause of the disease, providing hope for patients who previously had few alternatives.
Increasing Prevalence and Awareness: Improved diagnostic techniques and heightened awareness have led to an increase in the diagnosed cases of hATTR. This expansion of the patient pool has contributed to the growing demand for effective treatments like vutrisiran.
Regulatory Approvals and Market Expansion: Vutrisiran has received approvals from major regulatory bodies, including the U.S. FDA and the European Medicines Agency, facilitating its availability across multiple regions. This has expanded the market reach and accessibility of the drug.
Favorable Market Projections: The global vutrisiran market was valued at approximately USD 600 million in 2022 and is projected to reach around USD 2,087 million by 2033, exhibiting a compound annual growth rate (CAGR) of 12% during the forecast period.
Strategic Collaborations: Partnerships, such as the collaboration between Alnylam Pharmaceuticals and AstraZeneca, have bolstered the development and commercialization efforts for vutrisiran, enhancing its market presence and potential.
Competitive Landscape: While vutrisiran faces competition from other treatments like Pfizer's Vyndaqel and BridgeBio Pharma's acoramidis, its unique mechanism of action and positive clinical trial outcomes position it as a strong contender in the market.
Read More Details -
Other Latest Healthcare Trending Insights
Upper Limb Prosthetic Market:
Urea Cycle Disorder Market:
Ureteral Dilators Market:
Urodynamic Equipment Market:
Ustekinumab Market:
UV Spectroscopy Market:
Vaccine Delivery Device Market:
Vaccine Research Market:
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
Market Research Future
Market Research Future
+1 855-661-4441
email us here
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.
Comments
No comment